問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of General Internal Medicine

Division of Thoracic Medicine

更新時間：2023-09-19

鄭至宏
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

34Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

鄭至宏

List

45Cases

2023-10-16 - 2027-06-30

Phase III

Completed
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-3)

  • Condition/Disease

    severe eosinophilic asthma (EXHALE-3)

  • Test Drug

    tablets

Participate Sites
11Sites

Recruiting11Sites

2024-01-01 - 2025-12-31

Phase III

Completed
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 24 weeks in participants with eosinophilic asthma (EXHALE-4)

  • Condition/Disease

    eosinophilic asthma (EXHALE-4)

  • Test Drug

    tabltes

Participate Sites
9Sites

Recruiting9Sites

2025-06-01 - 2028-07-31

Phase III

Completed
An Open-Label Long-Term Phase III Extension Study to Assess the Long-Term Safety and Tolerability of Dexpramipexole in Participants with Severe Eosinophilic Asthma (EXHALE-5)

  • Condition/Disease

    Severe Eosinophilic Asthma

  • Test Drug

    tablet

Participate Sites
3Sites

Recruiting3Sites

2024-09-16 - 2027-09-24

Others

Active
A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial evaluating the efficacy and safety of 2 doses of buloxibutid over 52 weeks in people with idiopathic pulmonary fibrosis. (ASPIRE)

  • Condition/Disease

    • Absolute change from baseline in Forced Vital Capacity (FVC, mL) at Week 52

  • Test Drug

    Buloxibutid

Participate Sites
7Sites

Recruiting7Sites

2025-03-31 - 2028-06-30

Others

Not yet recruiting
A Retrospective, Observational, Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Infusions of Polymyxin B and Colistin Methanesulfonate in Patients with Carbapenem-Resistant Gram-Negative Bacterial Infection

  • Condition/Disease

    Carbapenem-Resistant Gram-Negative Bacterial Infection

  • Test Drug

    injection

Participate Sites
13Sites

Recruiting13Sites

2023-10-02 - 2028-01-05

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-10-16 - 2027-09-09

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2021-05-01 - 2023-10-30

Phase II

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis

  • Condition/Disease

    Pulmonary Fibrosis

  • Test Drug

    BMS-986278

Participate Sites
3Sites

Recruiting3Sites

2020-01-03 - 2021-03-08

Phase III

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of Efficacy and Safety of AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-associated Pneumonia (VAP) Caused by S. aureus

  • Condition/Disease

    AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-associated Pneumonia (VAP) Caused by S. aureus

  • Test Drug

    AR-301 Tosatoxumab

Participate Sites
10Sites

Not yet recruiting9Sites

Recruiting1Sites

2021-08-01 - 2023-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB